WO1994003170A1 - Metabolites de terfenadine et leurs isomeres optiquement purs utilises dans le traitement des affections allergiques - Google Patents

Metabolites de terfenadine et leurs isomeres optiquement purs utilises dans le traitement des affections allergiques Download PDF

Info

Publication number
WO1994003170A1
WO1994003170A1 PCT/US1993/007260 US9307260W WO9403170A1 WO 1994003170 A1 WO1994003170 A1 WO 1994003170A1 US 9307260 W US9307260 W US 9307260W WO 9403170 A1 WO9403170 A1 WO 9403170A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
pharmaceutical composition
formula
treatment
terfenadine
Prior art date
Application number
PCT/US1993/007260
Other languages
English (en)
Inventor
James W. Young
Nancy M. Gray
Raymond L. Woosley
Yiwang Chen
Original Assignee
Sepracor Inc.
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27129882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1994003170(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DK02006356T priority Critical patent/DK1214937T3/da
Priority to DE0701443T priority patent/DE701443T1/de
Priority to HU9500313A priority patent/HU226242B1/hu
Priority to DK93918584T priority patent/DK0701443T4/da
Priority to DE69316660T priority patent/DE69316660T3/de
Priority to PL93307339A priority patent/PL174373B1/pl
Priority to CA002141572A priority patent/CA2141572C/fr
Priority to BR9306841A priority patent/BR9306841A/pt
Priority to SK124-95A priority patent/SK12495A3/sk
Application filed by Sepracor Inc., Georgetown University filed Critical Sepracor Inc.
Priority to KR1019950700382A priority patent/KR950702420A/ko
Priority to EP93918584A priority patent/EP0701443B2/fr
Priority to RO95-00160A priority patent/RO116043B1/ro
Priority to GB9502183A priority patent/GB2284351B/en
Priority to AU47986/93A priority patent/AU675240B2/en
Priority to JP6505499A priority patent/JP3041954B2/ja
Publication of WO1994003170A1 publication Critical patent/WO1994003170A1/fr
Priority to NO19950374A priority patent/NO310644B1/no
Priority to FI950467A priority patent/FI950467A/fi
Priority to GR960300024T priority patent/GR960300024T1/el
Priority to GR980400714T priority patent/GR3026530T3/el
Priority to GR20010400247T priority patent/GR3035417T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to novel pharmaceutical compositions containing 4- [ 1-hydroxy-4- ( 4- hydroxydiphenylmethyl-1-piperidinyl )butyl ] - ⁇ , - dimethylbenzeneacetates and l-[p-(2-hydroxymethylprop-2- yl)-phenyl]-4-[4-( ⁇ -hydroxy- -phenylbenzyl) piperidin-1- yljbutanol and their optically pure derivatives.
  • compositions possess potent antihistaminic activity and are useful in treating allergic rhinitis, asthma and other allergic disorders while avoiding adverse effects associated with the administration of other o.-aryl-4- substituted piperidinoalkanol derivatives, such as terfenadine, including but not limited to cardiac arrhythmias, drowsiness, nausea, fatigue, weakness and headache.
  • these compositions in combination with non-steroidal anti-inflammatory agents or other non- narcotic analgesics, are useful for the treatment of cough, cold, cold-like, and/or flu symptoms and the discomfort, headache, pain, fever, and general malaise associated therewith.
  • the aforementioned combinations may optionally include one or more other active components including a decongestant, cough suppressant/antitussive, or expectorant.
  • the active compounds of these compositions and methods are metabolic derivatives of terf enadine.
  • the optical isomers of the compounds are methyl R-(+)-4-[l- hydroxy-4- ( 4 -hydroxydiphenylmethyl -1 -piper idiny 1 ) butyl ] - , ⁇ -dimethylbenzeneacetate , methyl S- ( - ) -4 - [ 1 -hydroxy-4 - ( 4 - hydroxydiphenylme hyl-1-piperidinyl )butyl]- ⁇ , ⁇ - dimethylbenzeneacetate , R- ( + ) -4- [ 1 -hydroxy-4- ( 4- hydroxydi phenyl methyl- 1-piperidinyl )butyl ] - ⁇ , ⁇ - dimethylbenzeneacetic acid, S-(-)-4-[ l-hydroxy-4-(4- hydroxydiphenylmethyl- 1-piperidinyl )butyl ] - ⁇ , ⁇ - dimethylbenzeneacetic acid, R-(+)-l
  • H-2 receptor-mediated responses histamine stimulates gastric acid secretion in the guinea pig and the chronotropic effect in isolated guinea pig atria.
  • Terfenadine has no effect on histamine-induced gastric acid secretion, nor does it alter the chronotropic effect of histamine on atria. Thus, terfenadine has no apparent effect on the H-2 histamine receptor. See Cheng et al., Drug Development Research, 2: 181-196 (1982). Terfenadine is well absorbed but is extensively metabolized. See Okerholm et al., Biophar aceutics and Drug Distribution, 2: 185-190 (1981).
  • terfenadine On the basis of its antihistaminic activity, researchers evaluated the effect of terfenadine in the treatment of allergic rhinitis . Clinical trials of efficacy indicated that terfenadine is slightly less effective than chlorpheniramine, another H-1 antagonist. See Connell, Pharmacotherapy, 5: 201-208 (1985). It has also been suggested that terfenadine would be useful for the treatment of asthma. In guinea pigs, the increase in airway resistance caused by LTD 4 (leukotriene the D-enantiomer of thalidomide was a safe and effective sedative when prescribed for the control of morning sickness during pregnancy, while the corresponding L- enantiomer has been believed to be a potent teratogen.
  • LTD 4 leukotriene the D-enantiomer of thalidomide was a safe and effective sedative when prescribed for the control of morning sickness during pregnancy, while the corresponding L- enantiomer has been believed to be
  • Terfenadine is an antagonist of the H-1 histamine receptor protein. Histamine receptor proteins occur in two well-identified forms in tissues as H-1 and H-2 receptors. The H-1 receptors are those that mediate the response antagonized by conventional antihistamines. H-1 receptors are present in the guinea pig ileum, the skin of Rhesus monkeys, and the bronchial smooth muscle of guinea pig. Terfenadine antagonizes the effect of histamine in the guinea pig isolated ileum, suppresses histamine-induced whealing in the skin of Rhesus monkeys, and protects against histamine induced lethality in the guinea pig.
  • H-2 receptor-mediated responses histamine stimulates gastric acid secretion in the guinea pig and the chronotropic effect in isolated guinea pig atria.
  • Terfenadine has no effect on histamine-induced gastric acid secretion, nor does it alter the chronotropic effect of histamine on atria. Thus, terfenadine has no apparent effect on the H-2 histamine receptor. See Cheng et al., Drug Development Research, 2: 181-196 (1982). Terfenadine is well absorbed but is extensively metabolized. See Okerholm et al., Biopharmaceutics and Drug Distribution, 2: 185-190 (1981).
  • terfenadine On the basis of its antihistaminic activity, researchers evaluated the effect of terfenadine in the treatment of allergic rhinitis . Clinical trials of efficacy indicated that terfenadine is slightly less effective than chlorpheniramine, another H-1 antagonist. See Connell, Pharmacotherapy, 5: 201-208 (1985). It has also been suggested that terfenadine would be useful for the treatment of asthma. In guinea pigs, the increase in airway resistance caused by LTD 4 (leukotriene D 4 ) was suppressed by terfenadine. See Akagi et al . , Oyo Yakuri, 35: 361-371 (1988).
  • Terfenadine may also be useful for the treatment of motion sickness and vertigo.
  • Some antihistamines have been found to be effective for the prophylaxis and treatment of motion sickness. See Wood, Drugs , 17: 471-479 (1979).
  • Some antihistamines have also proven useful for treating vestibular disturbances, such as Meniere's disease, and in other types of vertigo. See Cohen et al., Archives of Neurology, 27: 129-135 (1972).
  • terfenadine may be useful in the treatment of diabetic retinopathy and other small vessel disorders associated with diabetes mellitus.
  • treatment by antihistamines prevented the activation of retinal histamine receptors which have been implicated in the development of diabetic retinopathy.
  • the use of antihistamines to treat retinopathy and small vessel disorders associated with diabetes mellitus is disclosed in U.S. Patent No. 5,019,591.
  • terfenadine in combination with non-steroidal anti-inflammatory agents or other non-narcotic analgesics, would be useful for the treatment of cough, cold, cold-like and/or flu symptoms and the discomfort, pain, headache, fever, and general malaise associated therewith.
  • the present invention also includes methods for treating the above-described conditions in a human, while avoiding the adverse effects that are associated with terfenadine, including but not limited to cardiac arrhythmias, sedation, gastrointestinal distress, dry mouth, and constipation or diarrhea, by administering the metabolic derivatives of terfenadine or their optically pure isomers to said human.
  • compositions of the invention containing (1) metabolic derivatives of terfenadine or their optically pure isomers and (2) non-narcotic analgesics or non-steroidal anti-in lammatory agents such aspirin, acetaminophen or ibuprofen, may optionally include one or more other active components including a decongestant (such as pseudoephedrine) , a cough suppressant/antitussive (such as dextromethorphan) or an expectorant (such as guaifenesin) .
  • a decongestant such as pseudoephedrine
  • a cough suppressant/antitussive such as dextromethorphan
  • expectorant such as guaifenesin
  • the present invention encompasses a method of treating a human afflicted by or susceptible to an allergic disorder while avoiding the concomitant liability of adverse effects associated with the administration of terfenadine, lst Feb 1992, p. 33.
  • compositions containing metabolic derivatives of terfenadine or their optically pure isomers are useful in treating allergic disorders and such other conditions as may be related to the composition's activity as an antihistamine, including but not limited to allergic rhinitis, solar urticaria, and symptomatic dermographism.
  • the metabolic derivatives of terfenadine or their optically pure isomers are useful in treating asthma. Also, these compounds are useful for the treatment of motion sickness and vertigo and in treating such disorders as retinopathy and small vessel disorders associated with diabetes mellitus.
  • the present invention also includes methods for treating the above-described conditions in a human, while avoiding the adverse effects that are associated with terfenadine, including but not limited to cardiac arrhythmias, sedation, gastrointestinal distress, dry mouth, and constipation or diarrhea, by administering the metabolic derivatives of terfenadine or their optically pure isomers to said human.
  • compositions of the invention containing (1) metabolic derivatives of terfenadine or their optically pure isomers and (2) non-narcotic analgesics or non-steroidal anti-inflammatory agents such aspirin, acetaminophen or ibuprofen, may optionally include one or more other active components including a decongestant (such as pseudoephedrine) , a cough suppressant/antitussive (such as dextromethorphan) or an expectorant (such as guaifenesin) .
  • a decongestant such as pseudoephedrine
  • a cough suppressant/antitussive such as dextromethorphan
  • expectorant such as guaifenesin
  • the present invention encompasses a method of treating a human afflicted by or susceptible to an allergic disorder while avoiding the concomitant liability of adverse effects associated with the administration of terfenadine, which comprises administering to said human afflicted by or susceptible to an allergic disorder an amount of one or more compounds selected from the group of metabolic derivatives of terfenadine, optically pure isomers of metabolic derivatives of terfenadine, and pharmaceutically acceptable salts thereof, said amount being sufficient to treat said allergic disorder, but insufficient to cause the adverse effects associated with terfenadine.
  • the present invention provides a pharmaceutical composition comprising a compound of formula I:
  • Z is COOH, C00CH 3 or CH 2 OH, or a pharmaceutically acceptable salt thereof, for use in an anti-histaminic treatment which does not induce any significant cardiac arrhythmia, comprising administering a therapeutically effective amount of a compound of formula I to a human patient.
  • the compounds of formula I include the metabolic derivatives of terfenadine and the optically pure isomers of the metabolic derivatives of terfenadine as aforesaid.
  • a decongestant such as pseudoephedrine, or a pharmaceutically acceptable salt thereof.
  • the inventive composition comprises from 20mg to 200mg of a compound of formula I and from 25mg to 600mg of an anti-inflammatory agent or an analgesic.
  • the inventive composition comprises a therapeutically effective amount of a decongestant, it, preferably, comprises from 20mg to 200mg of a compound of formula I and from 5mg to 150mg of the decongestant.
  • the compound of formula I is in the form of a single optical isomer and the inventive composition is substantially free of the other such isomer.
  • the compound of formula I preferably, is selected from the group consisting of: methyl R-(+)-4-[l-hydroxy-4-(4-hydroxydiphenylmethyl-l- piperidinyl)butyl]- ⁇ , ⁇ -dimethylbenzeneacetate, R-(+)-4-[1- hydroxy-4-(4-hydroxydiphenylmethyl-1-piperidinyl)butyl]- ⁇ , ⁇ - dimethylbenzeneacetic acid, and R-(+ )-1-[p- ( 2- hydroxymethylprop-2-yl )phenyl ] -4- [ 4- ( ⁇ -hydroxy- ⁇ - phenylbenzyl)piperidin-l-yl]butanol and pharmaceutically acceptable salts thereof, and the composition is substantially free of the S stereoisomer of the selected compound; or,
  • the anti-histaminic treatment comprises the administration of a compound of formula I, in an amount of l-500mg/day and, preferably, in an amount of 20-200mg/day.
  • a compound of formula I in an amount of 0.01-500mg/day and, preferably, in an amount of 0.1-200mg/day.
  • the inventive composition further comprises a pharmaceutically acceptable carrier or excipient.
  • the composition can further comprise a therapeutically effective amount of a non-steroidal anti- inflammatory agent or a non-narcotic analgesic, such as acetylsalicylic acid, acetaminophen, ibuprofen, ketoprofen, or naproxen, or a pharmaceutically acceptable salt thereof.
  • a composition in accordance with the present invention can further comprise a therapeutically effective amount of a decongestant, such as pseudoephedrine, or a pharmaceutically acceptable salt thereof .
  • the inventive composition comprises from 20mg to 200mg of a compound of formula I and from 25mg to 600mg of an anti-inflammatory agent or an analgesic.
  • the inventive composition comprises a therapeutically effective amount of a decongestant, it, preferably, comprises from 20mg to 200mg of a compound of formula I and from 5mg to 150mg of the decongestant.
  • the compound of formula I is in the form of a single optical isomer and the inventive composition is substantially free of the other such isomer.
  • the compound of formula I preferably, is selected from the group consisting of: methyl R-(+)-4-[l-hydroxy-4-(4-hydroxydiphenylmethyl-1- piperidinyl)butyl]- ⁇ , ⁇ -dimethylbenzeneacetate, R-(+)-4-[ 1- hydroxy-4-(4-hydroxydiphenylmethyl-1-piperidiny1)butyl]- ⁇ , ⁇ - dimethylbenzeneacetic acid, and R- ( + ) -1- [p- ( 2- hydroxymethylprop- 2-yl )phenyl ] -4- [ 4- ( ⁇ -hydroxy- ⁇ - phenylbenzyl)piperidin-l-yl]butanol and pharmaceutically acceptable salts thereof, and the composition is substantially free of the S stereoisomer of the selected compound; or, is selected from
  • the compound of formula I comprises 90% or more of the selected R- or S-stereoisomer.
  • Z, in formula I is COOH and the compound of formula I is terfenadine carboxylate.
  • the invention in a second aspect, relates to a method of providing an anti-histaminic treatment which does not induce any significant cardiac arrhythmia, to a human patient, comprising administering a therapeutically effective amount of a pharmaceutical composition in accordance with the first aspect of the invention, preferably, in one of its preferred embodiments, to said human patient.
  • the inventive method is a method of treating a human afflicted by or susceptible to: an allergic disorder; motion sickness; vertigo; retinopathy, or another small vessel disease associated with diabetes mellitus; cough, cold, cold-like or flu symptoms; or the discomfort, pain, fever or general malaise associated therewith.
  • the method is a method for treating a human afflicated by or susceptible to an allergic disorder and, more preferably, the allergic disorder is asthma or allergic rhinitis.
  • the allergic disorder is asthma or allergic rhinitis.
  • - 18- isomers of the metabolic derivatives of terfenadine are also encompassed by the above-described definitions.
  • the term "substantially free of the R stereoisomer” as used herein means that the composition contains at least 90% by weight of the S isomer of the metabolic derivatives of terfenadine, and 10% by weight or less of the R derivatives. In a preferred embodiment, the term “substantially free of the R stereoisomer” means that the composition contains at least 99% by weight of the S isomer of the metabolic derivatives of terfenadine, and 1% or less of the R isomer. In another preferred embodiment, the term “substantially free of the R stereoisomer” as used herein means that the composition contains greater than 99% by weight of the S isomer of the metabolic derivatives of terfenadine and less than 1% by weight of the R derivatives.
  • terfenadine means that amount of one or more of the compounds of the invention which provides a therapeutic benefit in an anti-histaminic treatment, including the treatment or management of allergic disorders, asthma, retinopathy or other small vessel disorders index. It is, therefore, more desirable to use a metabolic derivative of terfenadine or an optically pure isomer thereof, than to use terfenadine itself.
  • the term “adverse effects” includes, but is not limited to cardiac arrhythmias, sedation, gastrointestinal distress, dry mouth, constipation, and diarrhea.
  • cardiac arrhythmias includes, but is not limited to ventricular tachyarrhythmias, torsades de pointes, and ventricular fibrillation.
  • substantially free of the S stereoisomer as used herein means that the metabolic derivative of terfenadine in a composition contains at least 90% by weight of the R isomer of the metabolic derivative of terfenadine, and 10% by weight or less of the S derivative.
  • the term "substantially free of the S stereoisomer” means that the metabolic derivative of terfenadine in a composition contains at least 99% by weight of the R isomer of the metabolic derivative of terfenadine, and 1% or less of the S isomer. In another preferred embodiment, the term “substantially free of the S stereoisomer” as used herein means that the metabolic derivative of terfenadine in a composition contains greater than 99% by weight of the R isomer of the metabolic derivative of terfenadine and less than 1% by weight of the S derivative.
  • substantially optically pure R isomers of the metabolic derivatives of terfenadine and “optically pure R isomers of the metabolic derivatives of terfenadine” are also encompassed by the above-described definitions.
  • the term "substantially free of the R stereoisomer” as used herein means that the composition contains at least 90% by weight of the S isomer of the metabolic derivatives of terfenadine, and 10% by weight or less of the R derivatives. In a preferred embodiment, the term “substantially free of the R stereoisomer” means that the composition contains at least 99% by weight of the S isomer of the metabolic derivatives of terfenadine, and 1% or less of the R isomer. In another preferred embodiment, the term “substantially free of the R stereoisomer” as used herein means that the composition contains greater than 99% by weight of the S isomer of the metabolic derivatives of terfenadine and less than 1% by weight of the R derivatives.
  • terapéuticaally effective amount means that amount of one or more of the compounds of the invention which provides a therapeutic benefit in an anti-histaminic treatment, including the treatment or management of allergic disorders, asthma, retinopathy or other small vessel disorders associated with diabetes mellitus, motion sickness, vertigo, or cough, cold, cold-like, and/or flu symptoms and the discomfort, pain, fever, and general malaise associated therewith.
  • allergic disorders include, but are not limited to, allergic rhinitis, solar urticaria, and symptomatic dermographism.
  • the symptoms associated with these allergic disorders and the cough, cold, cold-like, and/or flu symptoms include, but are not limited to, sneezing, rhinorrhea, lacrimation, and dermal irritation.
  • asthma is defined as a disorder characterized by increased responsiveness of the trachea and bronchi to various stimuli which results in symptoms which include wheezing, cough, and dyspnea.
  • verigo as used herein means the dizziness associated with, but not limited to motion, height, and changes in body position.
  • diabetes retinopathy or "retinopathy associated with diabetes mellitus” is that disorder caused by increased permeability of the capillaries in the eye which leads to hemorrhages and edema in the eye and can lead to blindness.
  • small vessel disorders associated with diabetes mellitus includes, but is not limited to diabetic retinopathy and peripheral vascular disease.
  • the separation of the optically pure isomers of the metabolic derivatives of terfenadine may be effected by resolution of the racemic mixture of enantiomers of the metabolic derivatives of terfenadine using conventional means -22- derivative of terfenadine, or an optically pure isomer, with (ii) a therapeutically effective amount of a decongestant," as well as the term "therapeutically effective amount of at least one ⁇ -aryl-4-substituted piperidinoalkanol derivative" are also encompassed by the above-described dosage amounts and dose frequency schedule.
  • any suitable route of administration may be employed for providing the patient with an effective dosage of the inventive composition.
  • oral, rectal, parenteral, transdermal, subcutaneous, intramuscular, and like forms of administration may be employed.
  • Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, patches, and the like.
  • compositions of the present invention comprise a metabolic derivative of terfenadine, or an optically pure isomer thereof as active ingredient, or a pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier, and optionally, other therapeutic ingredients .
  • pharmaceutically acceptable salts includes within its ambit salts prepared from pharmaceutically acceptable non-toxic acids or bases including inorganic acids or bases or organic acids or bases. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, sulfuric, and phosphoric. Appropriate organic acids may be selected, for example, from aliphatic, aromatic, carboxylic physician will know how and when to interrupt, adjust, or terminate therapy in conjunction with individual patient response.
  • an amount sufficient to alleviate said allergic disorder but insufficient to cause said adverse effects is encompassed by the above-described dosage amounts and dose frequency schedule.
  • a pharmaceutical composition for use in the treatment of cough, cold, cold-like and/or flu symptoms and the discomfort, pain, fever and general malaise associated therewith in a human, said composition comprising (i) a therapeutically effective amount of at least one metabolic derivative of terfenadine, or an optically pure isomer thereof, with (ii) a therapeutically effective amount of at least one non-steroidal anti-inflammatory agent or non- narcotic analgesic," and "a pharmaceutical composition for use in the treatment of cough, cold, cold-like and/or flu symptoms and the discomfort, pain, fever and general malaise associated therewith, in a human, said composition comprising (i) a therapeutically effective amount of at least one metabolic derivative of terfenadine, or an optically pure isomer, with (ii) a therapeutically effective amount of a decongestant," as well as the term "therapeutically effective amount of at least one ⁇ -aryl-4-substituted piperidinoalkanol derivative"
  • any suitable route of administration may be employed for providing the patient with an effective dosage of the inventive composition.
  • oral, rectal, parenteral, transdermal, subcutaneous, intramuscular, and like forms of administration may be employed.
  • Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, patches, and the like.
  • compositions of the present invention comprise a metabolic derivative of terfenadine, or an optically pure isomer thereof as active ingredient, or a pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier, and optionally, other therapeutic ingredients .
  • pharmaceutically acceptable salts includes within its ambit salts prepared from pharmaceutically acceptable non-toxic acids or bases including inorganic acids or bases or organic acids or bases. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, sulfuric, and phosphoric.
  • Appropriate organic acids may be selected, for example, from aliphatic, aromatic, carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, glycolic, glucoronic, maleic, furoic, glutamic, benzoic, anthranilic, salicylic, phenylacetic, mandelic, e bonic (pamoic), methanesulfonic, ethanesulfonic, pantothenic, benzenesulfonic, stearic, sulfanilic, algenic, and galacturonic.
  • inorganic bases include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium, and zinc.
  • Appropriate organic bases may be selected, for example, from N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumaine (N- methylglucamine) , lysine and procaine.
  • compositions of the present invention include compositions such as suspensions, solutions and elixirs; aerosols; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like, in the case of oral solid preparations (such as powders, capsules, and tablets) , with the oral solid preparations being preferred over the oral liquid preparations.
  • oral solid preparations such as powders, capsules, and tablets
  • the most preferred oral solid preparations are tablets.
  • tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques.
  • each tablet contains from about 10 mg to about 150 mg of the active ingredient
  • each cachet or capsule contains from about 10 mg to about 150 mg of the active ingredient, i.e., a metabolic derivative of terfenadine.
  • the tablet, cachet or capsule contains either one of three dosages, 30 mg, 60 mg or 90 mg of the active ingredient.
  • the mixture was extracted with ethyl acetate.
  • the ethyl acetate solution was washed with saturated aqueous sodium bicarbonate and brine and dried over sodium sulfate.
  • the ethyl acetate was removed on a rotary evaporator and the residue was treated with 25% ethyl acetate in hexane.
  • the resulting precipitate was filtered and air dried to give methyl 4-[l-oxo-4-(4- hydroxydiphenylmethyl-1-piperidinyl)butyl]- ⁇ , ⁇ - dimethylbenzeneacetate.
  • This intermediate precipitate (2.4 gm) was combined with tetrahydrofuran (10 ml) and (+)- ⁇ - chlorodiisopinocamphenylborane (4.5 gm) and stirred for 48 hours.
  • the mixture was diluted with ethyl acetate (200 ml) and washed with saturated aqueous sodium bicarbonate to give methyl R-4-[l-hydroxy-4-(4- hydroxydiphenylmethyl-1-piperidiny1)butyl]- ⁇ , ⁇ - dimethylbenzeneacetate.
  • Methyl S-4-[l-hydroxy-4-(4-hydroxydiphenylmethyl-l- piperidinyl)butyl]- ⁇ , ⁇ -dimethylbenzeneacetate (1.2 gm) was combined with potassium hydroxide (0.4 gm) and ethanol (5 ml) and the mixture was heated to reflux for 7 hours. The ethanol was removed on a rotary evaporator and the residue was dissolved in water (2 ml).
  • Single ventricular myocytes were obtained from isolated cat hearts by conventional techniques.
  • the rod- shaped single cells were maintained in a HEPES buffer and they were "patch clamped” using suction pipettes.
  • a Patch- Clamp L/M-PEC 7 amplifier was used to record current tracings and the recording electrodes were filled with a solution of potassium aspartate.
  • Voltage clamp pulses and data acquisition were controlled by a Sperry PC/IT Computer running P Clamp software.
  • a minimum of 4 cells were studied at each test concentration of the following drugs: racemic terfenadine, racemic terfenadine carboxylate, and quinidine (as a reference compound). Results were as follows:
  • a pharmaceutical composition comprising a compound of formula I:
  • Z is COOH, COOCH 3 or CH ? OH, or a pharmaceutically acceptable salt thereof, for use in an anti-histaminic treatment which does not induce any significant cardiac arrhythmia, comprising administering a therapeutically effective amount of a compound of formula I to a human patient.
  • a pharmaceutical composition, as claimed in claim 1, wherein the anti-histaminic treatment is a method of treating a human afflicted by or susceptible to: an allergic disorder; motion sickness; vertigo; retinopathy, or another small vessel disease associated with diabetes mellitus; cough, cold, cold ⁇ like or flu symptoms; or the discomfort, pain, fever or general malaise associated therewith. 4 .5 .
  • Example 5
  • the active ingredient which can instead be any substance.
  • (S)terfenadine carboxylate or racemic terfenadine carboxylate is sieved through a suitable sieve and blended with the lactose until a uniform blend is formed. Suitable volumes of water are added and the powders are granulated. After drying, the granules are then screened and blended with the magnesium stearate. The resulting granules are then compressed into tablets of desired shape. Tablets of other strengths may be prepared by altering the ratio of active ingredient to the excipient(s) or the compression weight.

Abstract

L'invention se rapporte à une composition pharmaceutique comprenant un composé de la formule (I) dans laquelle Z représente COOH, COOH3 ou CH2OH, ou un sel pharmaceutiquement acceptable de ce composé. Cette composition peut être utilisée dans un traitement anti-histaminique qui ne provoque aucune arythmie cardiaque importante, et le procédé consiste à administrer une quantité thérapeutiquement efficace d'un composé de la formule (I) à un être humain.
PCT/US1993/007260 1992-08-03 1993-08-03 Metabolites de terfenadine et leurs isomeres optiquement purs utilises dans le traitement des affections allergiques WO1994003170A1 (fr)

Priority Applications (20)

Application Number Priority Date Filing Date Title
KR1019950700382A KR950702420A (ko) 1992-08-03 1993-08-03 알레르기 질환 치료를 위한 테르페나딘 대사물과 그것의 광학 순수 이성체(terfenadine metabolites and their optically pure isomers for treating allergic disorders)
EP93918584A EP0701443B2 (fr) 1992-08-03 1993-08-03 Metabolites de terfenadine et leurs isomeres optiquement purs utilises dans le traitement des affections allergiques
DE0701443T DE701443T1 (de) 1992-08-03 1993-08-03 Terfanadin Metaboliten und deren optische reine Isomeren zur Behandlung vonallegischen Krankheiten
DK93918584T DK0701443T4 (da) 1992-08-03 1993-08-03 Terfenadinmetabolitter og deres optisk rene isomerer til behandling af allergiske lidelser
DE69316660T DE69316660T3 (de) 1992-08-03 1993-08-03 Terfanadin Metaboliten und deren optisch reine Isomere zur Behandlung von allergischen Krankheiten
PL93307339A PL174373B1 (pl) 1992-08-03 1993-08-03 Środek farmaceutyczny zawierający metabolit terfenadyny
CA002141572A CA2141572C (fr) 1992-08-03 1993-08-03 Metabolites de terfenadine et leurs isomeres optiquement purs pour le traitement des allergies
BR9306841A BR9306841A (pt) 1992-08-03 1993-08-03 Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
RO95-00160A RO116043B1 (ro) 1992-08-03 1993-08-03 Compozitie farmaceutica
DK02006356T DK1214937T3 (da) 1992-08-03 1993-08-03 Terfenadincarboxylat og behandling af hudirritation
JP6505499A JP3041954B2 (ja) 1992-08-03 1993-08-03 アレルギー疾患治療用のテルフェナジン代謝物及びその光学的に純粋な異性体
HU9500313A HU226242B1 (en) 1992-08-03 1993-08-03 Use of terfenadin carboxylic acid, their salt and optically pure isomers for the preparation of pharmaceutical compositions, and pharmaceutical compositions against allergic disorders
SK124-95A SK12495A3 (en) 1992-08-03 1993-08-03 Drug manufacturing process for use at antihistaminic treatment
GB9502183A GB2284351B (en) 1992-08-03 1993-08-03 Terfenadine metabolites and their optically pure isomers for treating allergic disorders
AU47986/93A AU675240B2 (en) 1992-08-03 1993-08-03 Terfenadine metabolites and their optically pure isomers for treating allergic disorders
NO19950374A NO310644B1 (no) 1992-08-03 1995-02-01 Anvendelse av terfenadinmetabolitt og dens optisk rene isomerer for fremstilling av et farmasöytisk preparat forbehandling av allergisk rhinitt
FI950467A FI950467A (fi) 1992-08-03 1995-02-02 Terfenadiinin metaboliitit ja niiden optisesti puhtaat isomeerit allergisten sairauksien hoitamiseksi
GR960300024T GR960300024T1 (en) 1992-08-03 1996-05-31 Terfenadine metabolites and their optically pure isomers for treating allergic disorders
GR980400714T GR3026530T3 (en) 1992-08-03 1998-04-03 Terfenadine metabolites and their optically pure isomers for treating allergic disorders
GR20010400247T GR3035417T3 (en) 1992-08-03 2001-02-14 Terfenadine metabolites and their optically pure isomers for treating allergic disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92418292A 1992-08-03 1992-08-03
US92415692A 1992-08-03 1992-08-03
US07/924,182 1992-08-03
US07/924,156 1992-08-03

Publications (1)

Publication Number Publication Date
WO1994003170A1 true WO1994003170A1 (fr) 1994-02-17

Family

ID=27129882

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/007260 WO1994003170A1 (fr) 1992-08-03 1993-08-03 Metabolites de terfenadine et leurs isomeres optiquement purs utilises dans le traitement des affections allergiques

Country Status (24)

Country Link
US (1) US5375693A (fr)
EP (4) EP1688142A1 (fr)
JP (6) JP3041954B2 (fr)
KR (1) KR950702420A (fr)
AT (3) ATE162399T1 (fr)
AU (3) AU675240B2 (fr)
BR (1) BR9306841A (fr)
CA (1) CA2141572C (fr)
CZ (1) CZ27495A3 (fr)
DE (5) DE701443T1 (fr)
DK (3) DK1214937T3 (fr)
ES (3) ES2257757T3 (fr)
FI (1) FI950467A (fr)
GB (1) GB2284351B (fr)
GR (3) GR960300024T1 (fr)
HK (1) HK1045806B (fr)
HU (1) HU226242B1 (fr)
NO (1) NO310644B1 (fr)
PL (1) PL174373B1 (fr)
PT (2) PT815860E (fr)
RO (1) RO116043B1 (fr)
RU (1) RU2167657C2 (fr)
SK (1) SK12495A3 (fr)
WO (1) WO1994003170A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5375693A (en) * 1992-08-03 1994-12-27 Sepracor, Inc. Methods and compositions for treating allergic disorders and other disorders metabolic derivatives of terfenadine
WO1995010278A1 (fr) * 1993-10-15 1995-04-20 Hoechst Marion Roussel, Inc. Traitement des troubles allergiques par le carboxylate de terfenadine
US5578610A (en) * 1993-06-24 1996-11-26 Albany Molecular Research, Inc. Piperidine derivatives
WO1997002824A1 (fr) * 1995-07-08 1997-01-30 Merck Sharp & Dohme Limited Utilisation d'un antagoniste de tachykinine et d'un antagoniste muscarinique et/ou d'une antihistamine dans le traitement du mal du transport
EP0818454A1 (fr) * 1996-06-04 1998-01-14 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes) Dérivés de benzimidazole à activité antihistaminique
WO1998033789A1 (fr) * 1997-02-04 1998-08-06 Sepracor, Inc. Synthese de terfenadine et ses derives
US5906747A (en) * 1995-11-13 1999-05-25 Biosepra Inc. Separation of molecules from dilute solutions using composite chromatography media having high dynamic sorptive capacity at high flow rates
US6039974A (en) * 1997-08-26 2000-03-21 Hoechst Marion Roussel, Inc. Pharmaceutical composition for combination of piperidinoalkanol-decongestant
US6113942A (en) * 1995-02-28 2000-09-05 Aventis Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol compounds
US6153754A (en) * 1995-12-21 2000-11-28 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US6201124B1 (en) 1995-12-21 2001-03-13 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US6509353B1 (en) 1998-04-14 2003-01-21 Sepracor Inc. Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
US6797826B2 (en) 1993-06-24 2004-09-28 Amr Technology, Inc. Piperidine derivatives and process for their production
US7135571B2 (en) 1994-05-18 2006-11-14 Aventis Pharmaceuticals, Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
EP1958935A2 (fr) 2000-11-08 2008-08-20 AMR Technology, Inc. Procédé de production de dérivés de pipéridine avec des micro-organismes
US7498443B2 (en) 2004-09-17 2009-03-03 Albany Molecular Research, Inc. Process for production of carebastine
US7498345B2 (en) 2004-09-17 2009-03-03 Albany Molecular Research, Inc. Process for production of piperidine derivatives

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0639976T3 (da) * 1992-05-11 1999-02-15 Merrell Pharma Inc Anvendelse af terfenadin-derivater som antihistaminika i patienter med leversygdomme
US20030045722A1 (en) * 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
US5455049A (en) * 1995-01-04 1995-10-03 Ascent Pharmaceuticals, Inc. Terfenadine oral powder
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5908850A (en) * 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5733756A (en) * 1996-01-05 1998-03-31 Celgene Corporation Lactams and processes for stereoselective enrichment of lactams, amides, and esters
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US6355656B1 (en) 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
DE19913862C2 (de) * 1999-03-26 2003-04-10 Forschungszentrum Juelich Gmbh Verfahren zur biokatalysierten Umsetzung schlecht wasserlöslicher Substanzen
DE10007203A1 (de) * 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
IL158334A0 (en) * 2001-04-09 2004-05-12 Teva Pharma Polymorphs of fexofenadine hydrochloride
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
WO2003020274A1 (fr) * 2001-08-30 2003-03-13 Aventis Pharmaceuticals Inc. Traitement de dermatite atopique
EP1474392A1 (fr) * 2002-06-10 2004-11-10 Teva Pharmaceutical Industries Ltd. Forme polymorphe xvi de l'hydrochlorure de fexofenadine
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
JP4515121B2 (ja) 2004-03-15 2010-07-28 東芝テック株式会社 ワイヤドットプリンタヘッド及びワイヤドットプリンタ
JP4473021B2 (ja) 2004-03-22 2010-06-02 東芝テック株式会社 窒化層形成方法、磁気回路形成部材、アーマチュア、ワイヤドットプリンタヘッド及びワイヤドットプリンタ
EP1628959A2 (fr) * 2004-04-26 2006-03-01 Teva Pharmaceutical Industries Ltd Formes cristallines d'hydrochlorure de fexofenadine, et procedes pour les preparer
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
US20060148851A1 (en) * 2004-09-28 2006-07-06 Shlomit Wizel Fexofenadine crystal form and processes for its preparation thereof
CA2591247A1 (fr) * 2004-12-09 2006-06-15 Celgene Corporation Traitement de patients atteints d'une maladie, presentant des antecedants familiaux ou ayant recu un diagnostic de tics ou du syndrome de la tourette, au moyen de d-threo methylphenidate
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
NZ581134A (en) * 2007-04-13 2011-04-29 Southern Res Institue Use of anti-angiogenic agents and methods of use, in particular bithionol for inhibiting or reducing angiogenesis
US20090076080A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched fexofenadine
WO2014052836A2 (fr) 2012-09-27 2014-04-03 Dunman Paul M Procédés et compositions de traitement d'une infection
JP6851365B2 (ja) 2015-03-26 2021-03-31 ジャクリーン・エム・イヴァーセン 宿酔に伴う症状を抑制するための方法及び組成物
DE102017130361A1 (de) 2017-12-18 2019-07-04 Lsp Innovative Automotive Systems Gmbh Statorzahn und Stator mit guter elektrischer Isolierung und gleichzeitig sehr hoher Wärmeleitfähigkeit zur Leistungssteigerung von Elektromotoren

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2453854A1 (fr) * 1979-04-10 1980-11-07 Richardson Merrell Inc Nouveaux derives d'o-(4-diphenylmethylpiperidino)-1-phenylalcanols, utiles notamment comme antihistaminiques, et leur procede de preparation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US880801A (en) † 1908-03-03 Harold Larsen Vibrator.
US922890A (en) † 1907-03-26 1909-05-25 Peder Joergen Hansen Stream-motor.
US4552899A (en) † 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4829064A (en) † 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4996061A (en) † 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
US4929605A (en) * 1987-10-07 1990-05-29 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol derivatives
MX9302076A (es) * 1992-04-10 1994-03-31 Merrell Dow Pharma Proceso novedoso para preparar derivados de piperidina.
DK0639976T3 (da) 1992-05-11 1999-02-15 Merrell Pharma Inc Anvendelse af terfenadin-derivater som antihistaminika i patienter med leversygdomme
ATE162399T1 (de) * 1992-08-03 1998-02-15 Sepracor Inc Terfanadin metaboliten und deren optisch reine isomere zur behandlung von allergischen krankheiten
DE69433346T2 (de) * 1993-06-24 2004-09-09 Albany Molecular Research, Inc. Herstellung von Verbindungen, die in der Produktion von Piperidin-Derivaten nützlich sind
EP1260504A1 (fr) * 1993-06-25 2002-11-27 Merrell Pharmaceuticals Inc. Préparation de dérivés de pipéridine 4-diphénylméthyl antihistaminiques
CA2128821A1 (fr) * 1993-07-27 1995-01-28 Dilip J. Gole Forme pharmaceutique lyophilisee et methode de separation
CA2128820A1 (fr) * 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Forme pharmaceutique a desintegration rapide et methode de preparation
WO1995010278A1 (fr) * 1993-10-15 1995-04-20 Hoechst Marion Roussel, Inc. Traitement des troubles allergiques par le carboxylate de terfenadine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2453854A1 (fr) * 1979-04-10 1980-11-07 Richardson Merrell Inc Nouveaux derives d'o-(4-diphenylmethylpiperidino)-1-phenylalcanols, utiles notamment comme antihistaminiques, et leur procede de preparation

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
B.TESTA ET AL.: "RACEMATES VERSUS ENANTIOMERS IN DRUG DEVELOPMENT: DOGMATISM OR PRAGMATISM?", CHIRALITY, vol. 2, 1990, pages 129 - 133 *
D.A.GARTEIZ ET AL.: "PHARMACOKINETICS AND BIOTRANSFORMATION STUDIES OF TERFENADINE IN MAN", ARZNEIM.-FORSCH./DRUG RES., vol. 32(II), no. 9A, 1982, pages 1185 - 1190 *
E.J.ARIENS: "RACEMIC THERAPEUTICS - ETHICAL AND REGULATORY ASPECTS", EUR.J.CLIN.PHARMACOL., vol. 41, no. 2, 1991, pages 89 - 93 *
E.J.ARIENS: "RACEMISCHE THERAPEUTICA PROBLEEMMIDDELEN", PHARMACEUTISCH WEEKBLAD, vol. 125, no. 2, 1 June 1990 (1990-06-01), pages 552 - 554 *
E.J.ARIENS: "STEREOSELECTIVITY IN PHARMACODYNAMICS AND PHARMACOKINETICS", SCHWEIZ.MED.WOCHENSCHR., vol. 120, no. 5, 3 February 1990 (1990-02-03), pages 131 - 134 *
J.E.COUTANT ET AL.: "DETERMINATION OF TERFENADINE AND TERFENADINE ACID METABOLITE...", J.CHROMATOGRAPHY, vol. 570, no. 1, 18 September 1991 (1991-09-18), pages 139 - 148 *
K.TASAKA ET AL.: "ANTIALLERGIC EFFECTS OF TERFENADINE...", YAKURI TO CHIRYO, vol. 16, no. 6, 1988, pages 2465 - 2480 *
K.TASAKA ET AL.: "INTRACELLULAR CALCIUM...", ANN.ALLERGY, vol. 56, no. 6, June 1986 (1986-06-01), pages 464 - 469 *
K.Y.CHAN ET AL.: "DIRECT ENANTIOMERIC SEPARATION...", J.CHROMATOGRAPHY, vol. 571, no. 1-2, 1991, pages 291 - 297 *
K.Y.CHAN ET AL.: "LACK OF INTERCONVERSION OF THE ENANTIOMERS OF TERFENADINE IN VIVO...", PHARM.RES., vol. 7, no. SUPP, September 1990 (1990-09-01), pages S222 *
K.ZAMANI ET AL.: "ENANTIOMERIC ANALYSIS OF TERFENADINE IN RAT PLASMA BY HPLC", CHIRALITY, vol. 3, no. 6, 1991, pages 467 - 470 *
M.AKAGI ET AL.: "ANTIALLERGIC EFFECTS OF TERFENADINE...", IMMUNOPHARMACOL.IMMUNOTOXICOL., vol. 9, no. 2-3, 1987, pages 259 - 279 *
P.K.HONIG ET AL.: "CHANGES IN THE PHARMACOKINETICS...", CLIN.PHARMACOL.THER., vol. 52, no. 3, September 1992 (1992-09-01), pages 231 - 238 *
pages 1550 - 1552 *
R.L.WOOSLEY: "MECHANISM OF THE CARDIOTOXIC ACTIONS OF TERFENADINE", JAMA, vol. 269, no. 12, 24 March 1993 (1993-03-24), pages 1532 - 1536 *
T.-M.CHEN ET AL.: "DETERMINATION OF THE METABOLITES OF TERFENADINE...", J.PHARM.BIOMED.ANAL., vol. 9, 1991, pages 929 - 933 *

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5375693A (en) * 1992-08-03 1994-12-27 Sepracor, Inc. Methods and compositions for treating allergic disorders and other disorders metabolic derivatives of terfenadine
US7390906B2 (en) 1993-06-24 2008-06-24 Amr Technology, Inc. Piperidine derivatives and process for their production
EP1026147A1 (fr) * 1993-06-24 2000-08-09 Albany Molecular Research, Inc. Composés qui sont utilisés comme intermediaires pour la préparation de dérivés de piperidine
US7238834B2 (en) 1993-06-24 2007-07-03 Amr Technology, Inc. Piperidine derivatives and process for their production
US5589487A (en) * 1993-06-24 1996-12-31 Albany Molecular Research, Inc. Piperidine derivatives and process for their production
US7022880B2 (en) 1993-06-24 2006-04-04 Amr Technology , Inc. Piperidine derivatives and process for their production
US5578610A (en) * 1993-06-24 1996-11-26 Albany Molecular Research, Inc. Piperidine derivatives
US5750703A (en) * 1993-06-24 1998-05-12 Albany Molecular Research, Inc. Piperidine derivatives and process for their production
US5581011A (en) * 1993-06-24 1996-12-03 Albany Molecular Research, Inc. Aromatic ketones and processes for their preparation
US6797826B2 (en) 1993-06-24 2004-09-28 Amr Technology, Inc. Piperidine derivatives and process for their production
WO1995010278A1 (fr) * 1993-10-15 1995-04-20 Hoechst Marion Roussel, Inc. Traitement des troubles allergiques par le carboxylate de terfenadine
US7138524B2 (en) 1994-05-18 2006-11-21 Aventis Pharmaceuticals, Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
US7135571B2 (en) 1994-05-18 2006-11-14 Aventis Pharmaceuticals, Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
US7666881B2 (en) 1994-05-18 2010-02-23 Aventis Holdings, Inc. Methods of treating allergic reactions using hydrated forms of antihistaminic piperidine derivatives
US7662835B2 (en) 1994-05-18 2010-02-16 Aventis Holdings, Inc. Methods of treating allergic reactions using an anhydrous form of antihistaminic piperidine derivatives
US8129408B2 (en) 1995-02-28 2012-03-06 Aventisub Ii Inc. Pharmaceutical composition for piperidinoalkanol compounds
US6113942A (en) * 1995-02-28 2000-09-05 Aventis Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol compounds
JP2008266347A (ja) * 1995-02-28 2008-11-06 Aventis Pharmaceuticals Inc ピペリジノアルカノール化合物のための医薬組成物
US6140324A (en) * 1995-07-08 2000-10-31 Merck Sharp & Dohme Ltd. Use of a tachykinin antagonist and a muscarinic antagonist and/or an antihistamine to treat motion sickness
WO1997002824A1 (fr) * 1995-07-08 1997-01-30 Merck Sharp & Dohme Limited Utilisation d'un antagoniste de tachykinine et d'un antagoniste muscarinique et/ou d'une antihistamine dans le traitement du mal du transport
US5906747A (en) * 1995-11-13 1999-05-25 Biosepra Inc. Separation of molecules from dilute solutions using composite chromatography media having high dynamic sorptive capacity at high flow rates
US6458958B1 (en) 1995-12-21 2002-10-01 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US6452011B1 (en) 1995-12-21 2002-09-17 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US8022220B2 (en) 1995-12-21 2011-09-20 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US6448406B1 (en) 1995-12-21 2002-09-10 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US6919458B2 (en) 1995-12-21 2005-07-19 Amr Technology, Inc. Process for production of piperidine derivatives
US6974872B2 (en) 1995-12-21 2005-12-13 Amr Technology, Inc. Process for production of piperidine derivatives
US6444824B1 (en) 1995-12-21 2002-09-03 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US6201124B1 (en) 1995-12-21 2001-03-13 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US6153754A (en) * 1995-12-21 2000-11-28 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US7678915B2 (en) 1995-12-21 2010-03-16 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US7560561B2 (en) 1995-12-21 2009-07-14 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US8476445B2 (en) 1995-12-21 2013-07-02 Albany Molecular Research, Inc. Process for production of piperidine derivatives
ES2124167A1 (es) * 1996-06-04 1999-01-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
EP0818454A1 (fr) * 1996-06-04 1998-01-14 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes) Dérivés de benzimidazole à activité antihistaminique
US5925761A (en) * 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
WO1998033789A1 (fr) * 1997-02-04 1998-08-06 Sepracor, Inc. Synthese de terfenadine et ses derives
US6147217A (en) * 1997-02-04 2000-11-14 Sepracor Inc. Synthesis of terfenadine and derivatives
US6039974A (en) * 1997-08-26 2000-03-21 Hoechst Marion Roussel, Inc. Pharmaceutical composition for combination of piperidinoalkanol-decongestant
US8404715B2 (en) 1998-04-14 2013-03-26 Sunovion Pharmaceuticals Inc. Methods and compositions using racemic, (R)-, and (S)-fexofenadine in combination with leukotriene inhibitors
US6509353B1 (en) 1998-04-14 2003-01-21 Sepracor Inc. Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
EP1958935A2 (fr) 2000-11-08 2008-08-20 AMR Technology, Inc. Procédé de production de dérivés de pipéridine avec des micro-organismes
US7498443B2 (en) 2004-09-17 2009-03-03 Albany Molecular Research, Inc. Process for production of carebastine
US8067605B2 (en) 2004-09-17 2011-11-29 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US8067604B2 (en) 2004-09-17 2011-11-29 Albany Molecular Research, Inc. Process for production of carebastine
US7863452B2 (en) 2004-09-17 2011-01-04 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US7498345B2 (en) 2004-09-17 2009-03-03 Albany Molecular Research, Inc. Process for production of piperidine derivatives

Also Published As

Publication number Publication date
GR3026530T3 (en) 1998-07-31
EP1214937A3 (fr) 2002-10-30
HK1045806A1 (en) 2002-12-13
JP2000086513A (ja) 2000-03-28
HU226242B1 (en) 2008-07-28
RU2167657C2 (ru) 2001-05-27
DK0701443T4 (da) 2000-12-18
EP0815860A2 (fr) 1998-01-07
DE69334145T2 (de) 2008-01-24
HUT71889A (en) 1996-02-28
DE701443T1 (de) 1997-01-30
JP2000086516A (ja) 2000-03-28
JP2000086515A (ja) 2000-03-28
FI950467A (fi) 1995-03-31
EP0815860B1 (fr) 2006-04-12
ES2284740T3 (es) 2007-11-16
JP3041954B2 (ja) 2000-05-15
DK1214937T3 (da) 2007-09-17
HU9500313D0 (en) 1995-03-28
EP1688142A1 (fr) 2006-08-09
HK1045806B (zh) 2008-03-14
ATE162399T1 (de) 1998-02-15
GB2284351B (en) 1996-11-27
ATE363283T1 (de) 2007-06-15
BR9306841A (pt) 1998-12-08
NO950374D0 (no) 1995-02-01
ES2086270T5 (es) 2001-02-01
CA2141572C (fr) 2001-02-06
DE69316660D1 (de) 1998-02-26
JP3288662B2 (ja) 2002-06-04
FI950467A0 (fi) 1995-02-02
RO116043B1 (ro) 2000-10-30
RU95107881A (ru) 1996-11-27
JP3288660B2 (ja) 2002-06-04
JP2000086512A (ja) 2000-03-28
DE69334008T2 (de) 2006-10-19
EP0701443B1 (fr) 1998-01-21
DE69316660T2 (de) 1998-05-07
PT1214937E (pt) 2007-07-25
EP0701443A1 (fr) 1996-03-20
CA2141572A1 (fr) 1994-02-17
US5375693A (en) 1994-12-27
DE69334145D1 (de) 2007-07-12
GR960300024T1 (en) 1996-05-31
CZ27495A3 (en) 1996-09-11
JP3288661B2 (ja) 2002-06-04
EP1214937B1 (fr) 2007-05-30
AU675240B2 (en) 1997-01-30
JPH08500348A (ja) 1996-01-16
JP2000086514A (ja) 2000-03-28
DE69316660T3 (de) 2001-04-05
EP0701443B2 (fr) 2000-11-22
PL307339A1 (en) 1995-05-15
ES2086270T3 (es) 1998-03-01
PT815860E (pt) 2006-08-31
AU4798693A (en) 1994-03-03
NO950374L (no) 1995-03-29
AU1842999A (en) 1999-04-29
DE69334008D1 (de) 2006-05-24
KR950702420A (ko) 1995-07-29
ATE322899T1 (de) 2006-04-15
JP3037697B2 (ja) 2000-04-24
ES2257757T3 (es) 2006-08-01
SK12495A3 (en) 1997-01-08
ES2086270T1 (es) 1996-07-01
GB9502183D0 (en) 1995-03-22
DK0701443T3 (da) 1998-02-09
DK0815860T3 (da) 2006-08-14
AU7182296A (en) 1997-01-30
EP1214937A2 (fr) 2002-06-19
GB2284351A (en) 1995-06-07
GR3035417T3 (en) 2001-05-31
EP0815860A3 (fr) 1998-01-14
NO310644B1 (no) 2001-08-06
PL174373B1 (pl) 1998-07-31
DE9320925U1 (de) 1995-08-31

Similar Documents

Publication Publication Date Title
US5375693A (en) Methods and compositions for treating allergic disorders and other disorders metabolic derivatives of terfenadine
US6124320A (en) Methods for treating allergic disorders using norastemizole
US6384054B1 (en) Compositions for treating allergic and other disorders using norastemizole in combination with other active ingredients
AU782660B2 (en) Terfenadine metabolites and their optically pure isomers for treating allergic disorders
AU7252700A (en) Use of norastemizole for the treatment of allergic disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2141572

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 950467

Country of ref document: FI

Ref document number: 95-00160

Country of ref document: RO

WWE Wipo information: entry into national phase

Ref document number: 1993918584

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1993918584

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1993918584

Country of ref document: EP